Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharma

Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is wholly owned by the PE group. Now post merger, Advent will own 66.7% in the combined entity and the public shareholders the rest.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news